The up-regulation of lincRNA ANRIL, also called CDKN2B antisense RNA 1 (CDKN2B-AS1),has been described in many different cancers and correlated with tumor progression [120,121,122]. This evidence concerns the gene CDKN2B-AS1 and neoplasm.